- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sonus gains additional European approval
The European Medicines Evaluation Agency has approved the remaining manufacturing variation in Sonus Pharmaceuticals’ European marketing authorization for EchoGen, Sonus’ ultrasound contrast agent. The EMEA approval enables Sonus to begin
The European Medicines Evaluation Agency has approved the remaining manufacturing variation in Sonus Pharmaceuticals European marketing authorization for EchoGen, Sonus ultrasound contrast agent. The EMEA approval enables Sonus to begin production of EchoGen in Europe. The Bothell, WA-based company is currently in discussions with potential marketing partners in Europe and expects to have several of these relationships in place early this year. In November, Sonus took back exclusive marketing rights to EchoGen in Europe, Latin America, Canada, the Middle East, and certain Asia Pacific countries from its previous marketing partner outside the U.S., Abbott International (SCAN 11/27/99).
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
